Marker Therapeutics, Inc.
MRKR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.05 | 0.16 | -0.03 |
| FCF Yield | -18.29% | -8.80% | -40.26% | -16.62% |
| EV / EBITDA | 1.23 | -2.56 | 0.01 | 3.34 |
| Quality | ||||
| ROIC | -11.62% | -40.62% | -31.80% | -21.08% |
| Gross Margin | 0.00% | -385.04% | 100.00% | -125.89% |
| Cash Conversion Ratio | 1.37 | 0.47 | 1.24 | 1.23 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.92% | 12.78% | 14.61% | 23.33% |
| Free Cash Flow Growth | -45.65% | 65.85% | -16.94% | -492.75% |
| Safety | ||||
| Net Debt / EBITDA | 8.23 | 2.46 | 3.08 | -7.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 121.55 | 138.03 | 633.88 | 74.92 |